Preservative-free versus preserved latanoprost eye drops for reducing intraocular pressure: a non-inferiority phase III randomized, multi-center, single-blind, parallel-group controlled trial

  • سال انتشار: 1399
  • محل انتشار: مجله نظریه پردازی در چشم پزشکی، دوره: 9، شماره: 4
  • کد COI اختصاصی: JR_MEOP-9-4_006
  • زبان مقاله: انگلیسی
  • تعداد مشاهده: 123
دانلود فایل این مقاله

نویسندگان

Panos Theodosiadis

Anastasios Konstas

Ioannis Halkiadakis

Vasiliki Dimera

Dimitrios Koufakis

Constantinos D Georgakopoulos

Evgenia Kanonidou

Elias Zintzaras

Konstantina Soulele

Antonios Margaritis

Lida Kalantzi

چکیده

Abstract Background: The aim of this study was to test the non-inferiority of preservative-free (PF) latanoprost ۵۰ micrograms per milliliter multi-dose ophthalmic solution versus the marketed benzalkonium chloride (BAK)-preserved latanoprost ۵۰ micrograms per milliliter ophthalmic solution in patients with open-angle glaucoma and patients with ocular hypertension. Methods: This was a prospective, national, randomized, multi-center, observer-blind, parallel-group controlled clinical trial. Patients were randomized to receive either PF or BAK-preserved latanoprost once daily for ۱۲ weeks. The primary endpoint was the change in intraocular pressure (IOP) at ۸:۰۰ AM in the affected eye between the end of the treatment (week ۱۲) and the baseline (week ۰). Secondary measurements were taken at weeks ۲ and ۶, with IOP being recorded at ۸:۰۰ AM, ۱۲:۰۰ PM, and ۴:۰۰ PM. Results: A total of ۱۵۸ patients were included in the per protocol (PP) population (۷۷ in the PF latanoprost treatment arm and ۸۱ patients in the BAK-preserved latanoprost treatment arm). PF latanoprost was non-inferior to BAK-preserved latanoprost in reducing IOP at ۸:۰۰ AM in the study eye from the baseline (week ۰) to the end of the treatment (week ۱۲). The point estimate of the between-treatment difference was ۰.۱ mmHg (۹۵% confidence interval: -۰.۶۴۶, ۰.۸۴۷). Mean between-group differences in IOP reduction from the baseline to each of the secondary measurements were also similar between the two treatment arms. The two treatments were well tolerated and had comparable adverse event profiles. Conclusions: PF latanoprost was non-inferior to BAK-preserved latanoprost in reducing IOP in patients with open-angle glaucoma or ocular hypertension. Both treatments were well tolerated.

کلیدواژه ها

اطلاعات بیشتر در مورد COI

COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.

کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.